enGene (ENGN) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary

Product profile and market positioning

• Detalimogene offers competitive efficacy and best-in-class tolerability, with low treatment discontinuation and interruptions, fitting well into community urology practices due to its non-viral, easy-to-handle formulation and flexible storage requirements.

• Over 80% of NMIBC patients are managed in community settings, where throughput, ease of use, and practice economics are highly valued.

• Recent market innovations, such as J&J's INLEXZO and TAR-200, set new benchmarks for efficacy and pricing, influencing detalimogene's commercial strategy.

• Detalimogene's low cost of goods provides pricing flexibility, allowing adaptation to evolving market benchmarks.

Clinical development and regulatory progress

• The pivotal LEGEND study fully enrolled 125 patients, exceeding the initial target due to high interest.

• Interim data showed a six-month complete response rate of 62%, with low adverse events and minimal treatment interruptions, supporting a best-in-class tolerability profile.

• Durability data are promising, with all evaluable patients at nine months maintaining complete response, and expectations for strong 12-month durability.

• The primary endpoint was updated to align with FDA standards, focusing on complete response rate at any time.

• Top-line data are expected in the second half of the year, with regulatory filing planned shortly after, supported by strong FDA engagement and special designations (RMAT, CDRP).

Manufacturing, study design, and future expansion

• Manufacturing is nearly complete, with a unique non-viral process and ongoing FDA validation, de-risked by early and open regulatory dialogue.

• The study includes 94 post-amendment patients (driving results) and 31 pre-amendment patients (minimal impact), with regulatory discussions ongoing regarding analysis.

• Additional LEGEND study cohorts (BCG-naive, BCG-exposed, papillary) are deprioritized for now but may support future label expansions and guideline inclusion.

• Intermediate-risk NMIBC is a future target, leveraging detalimogene's ease of use and tolerability.